Factors associated with corticosteroid therapy failure in HTLV–associated spastic paraparesis in an endemic region of Peru

Raul Montalvo; Lizbeth Lizana-Quispe; Thalia Porta-Quinto; Ciro Rodriguez; Kelina Almora-León; Jenny Julian; Edith Lozano-Orihuela

doi:10.54034/mic.e2695

Authors

Raul Montalvo Universidad Nacional del Centro del Perú, Huancayo, Perú
Lizbeth Lizana-Quispe Universidad Nacional del Centro del Perú, Huancayo, Perú
Thalia Porta-Quinto Universidad Nacional del Centro del Perú, Huancayo, Perú
Ciro Rodriguez Universidad Nacional del Centro del Perú, Huancayo, Perú
Kelina Almora-León Hospital Nacional del Centro Daniel Alcides Carrión, Huancayo, Perú
Jenny Julian Universidad Nacional del Centro del Perú, Huancayo, Perú
Edith Lozano-Orihuela Universidad Nacional del Centro del Perú, Huancayo, Perú

DOI:

https://doi.org/10.54034/mic.e2695

Keywords:

HTLV-1, HTLV-2, spastic paraparesis, corticosteroids, treatment failure, risk factors

Abstract

Introduction. HTLV-1/2–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic progressive myelopathy with variable response to corticosteroids. In endemic regions such as central Peru, evidence on predictors of treatment failure remains limited. Methods. Analytical cross-sectional study of patients with confirmed HTLV-1/2–associated spastic paraparesis treated with corticosteroids (2018–2024) at a tertiary hospital in Huancayo, Peru. Treatment failure was defined as no improvement or worsening on the Osame Motor Disability Score (OMDS). Sociodemographic data, disease duration, comorbidities, and OMDS were extracted from medical records. Bivariate (chi-square) and multivariable logistic regression analyses were performed (p<0.05). Results. Thirty-eight patients were included (median age 55 years, 63.2% female; median disease duration 4 years). In bivariate analysis, disease duration >7 years, comorbidities, and severe disability OMDS >7) were associated with treatment failure. After multivariable adjustment, only severe disability remained independently associated (OR 14.77; 95% CI 2.08–104.93; p=0.007). Disease duration >7 years and comorbidities lost significance (p>0.05). Conclusions. Severe neurological disability (OMDS >7) is the main independent predictor of corticosteroid treatment failure in HAM/TSP. Baseline functional status appears more relevant than disease duration or sociodemographic factors. Early intervention is needed in advanced cases.

References

1. Martel M, Gotuzzo E. HTLV-1 is also a sexually transmitted infection. Front Public Health. 2022;10:840295. https://doi.org/10.3389/fpubh.2022.840295

2. Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection: an emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Rev Esp Quimioter. 2019;32(6):485–496.

3. Gotuzzo Herencia E, González Lagos E, Verdonck Bosteels K, Mayer Arispe E, Ita Nagy F, Clark Leza D. Veinte años de investigación sobre HTLV-1 y sus complicaciones médicas en el Perú: perspectivas generales. Acta Med Peru. 2010;27(3):196–203.

4. Schierhout G, McGregor S, Gessain A, Einsiedel L, Martinello M, Kaldor J. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20(1):133–143. https://doi.org/10.1016/S1473-3099(19)30402-5

5. National Institute of Neurological Disorders and Stroke. HTLV-1-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) [Internet]. 2024.

6. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. https://doi.org/10.3389/fmicb.2012.00388

7. Franzoi AC, Araújo AQC. Disability profile of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis using the Functional Independence Measure. Spinal Cord. 2005;43(4):236–240. https://doi.org/10.1038/sj.sc.3101693

8. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2003;9(1):29–35. https://doi.org/10.1080/13550280390173270

9. Araujo A, Bangham CRM, Casseb J, Gotuzzo E, Jacobson S, Martin F, et al. Management of HAM/TSP: systematic review and consensus-based recommendations. Neurol Clin Pract. 2021;11(1):49–56. https://doi.org/10.1212/CPJ.0000000000000832

10. Coler-Reilly ALG, Sato T, Matsuzaki T, Nakagawa M, Niino M, Nagai M, et al. Effectiveness of daily prednisolone to slow progression of HTLV-1-associated myelopathy/tropical spastic paraparesis: a multicenter retrospective cohort study. Neurotherapeutics. 2017;14(4):1084–1094. https://doi.org/10.1007/s13311-017-0557-1

11. Croda MG, de Oliveira ACP, Vergara MPP, Bonasser F, Smid J, Duarte AJS, et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10-year open cohort. J Neurol Sci. 2008;269(1-2):133–137. https://doi.org/10.1016/j.jns.2007.12.029

12. Alberti C, Cartier L, Valenzuela MA, Puente J, Tanaka Y, Ramirez E. Molecular and clinical effects of betamethasone in HTLV-I-associated myelopathy/tropical spastic paraparesis patients. J Med Virol. 2011;83(9):1641–1649. https://doi.org/10.1002/jmv.22158

13. Yamauchi J, Tanabe K, Sato T, Nakagawa M, Matsuura E, Tsuboi Y, et al. Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P). Viruses. 2022;14(1):136. https://doi.org/10.3390/v14010136

14. Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, et al. Cerebrospinal fluid CXCL10 as a candidate surrogate marker for HTLV-1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2019;10:2110. https://doi.org/10.3389/fmicb.2019.02110

15. Buell KG, Puri A, Demontis MA, Short CL, Adonis A, Haddow J, et al. Effect of pulsed methylprednisolone on pain in patients with HTLV-1-associated myelopathy. PLoS One. 2016;11(4):e0152557. https://doi.org/10.1371/journal.pone.0152557

16. Calahorrano Flores JE. Relación entre las características clínicas y biomarcadores virológicos e inmunológicos en pacientes con paraparesia espástica tropical asociada a HTLV-1 [tesis]. Lima: Universidad Peruana Cayetano Heredia; 2024.

17. Carita Navarro FA. Sistema experto para el diagnóstico de paraparesia espástica tropical asociado al HTLV-1 [tesis]. Andahuaylas: Universidad Nacional José María Arguedas; 2019.

18. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):7415–7419.

19. Schoch CL, Ciufo S, Domrachev M, Hotton CL, Kannan S, Khovanskaya R, et al. NCBI taxonomy: a comprehensive update on curation, resources and tools. Database (Oxford). 2020;2020:baaa062. https://doi.org/10.1093/database/baaa062

20. Taylor GP. The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S8–S14.

21. Osame M, Igata A, Usuku K, Rosales RL, Matsumoto M. HTLV-I-associated myelopathy, a new clinical entity. Lancet. 1986;1(8488):1031–1032.

22. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus associated with a T-cell variant of hairy cell leukemia. Science. 1982;218(4572):571–573.

23. Martinez MP, Al-Saleem J, Green PL. Comparative virology of HTLV-1 and HTLV-2. Retrovirology. 2019;16(1):21. https://doi.org/10.1186/s12977-019-0483-0

24. Alarcón JO, Friedman HB, Montano SM, Zunt JR, Holmes KK, Quinnan GV. High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in Peru. J Acquir Immune Defic Syndr. 2006;42(5):604–609.

25. Miranda-Ulloa E, Romero-Ruiz S, Montalvo-Otivo R, Suárez-Agüero D, Quiroz-Ruiz HR, Valverde-Ticlia F, et al. Distribución geográfica y tipo de infección del virus linfotrópico T humano en pacientes peruanos, 2019–2021. Rev Chil Infectol. 2023;40(2):193–196.

26. Eiraku N, Novoa P, da Costa Ferreira M, Monken C, Ishak R, da Costa Ferreira O, et al. Identification and characterization of a new and distinct molecular subtype of HTLV-1. J Virol. 1996;70(3):1481–1492.

27. Oliveira-Filho AB, Frade PCR, Fonseca RRS, Sawada L, Martins LC, Machado LFA, et al. Spread of human T-lymphotropic virus 1 and 2 among relatives of people who use illicit drugs in northern Brazil. Front Microbiol. 2022;13:889948. https://doi.org/10.3389/fmicb.2022.889948

28. Correa LP, da Costa Farias F, dos Santos Barile KA, Palmeira MK, de Melo Amaral CE. Human T-lymphotropic virus 2 prevalence among blood donors in the state of Pará, Brazil. Braz J Microbiol. 2023;54(3):1745–1750. https://doi.org/10.1007/s42770-023-01047-w

29. Montalvo R, Vilcapoma P, Pomazongo M, Mathey C, Montalvo M. Oesophageal and oral ulcer tuberculous associated with HTLV-1 and SARS-CoV-2 infection. J Commun Dis. 2022;54(1):123–126.

30. Montalvo R, Ramírez MC, Damián M, Bruno A, Vilchez S, Quisurco M. Presentación inusual de infección por HTLV-1: una caja de pandora de infecciones oportunistas. Rev Argent Dermatol. 2018;99(2):1–10.

31. Cartier L, Ramírez E, Galeno H. Forma familiar de la paraparesia espástica tropical: reporte de 4 familias. Rev Med Chil. 1998;126(4):419–426.

32. Miranda-Acuña J, Tovar-Llanos V, Montaño JM. Mielopatía asociada con infección por HTLV-1: paraparesia espástica tropical. Acta Neurol Colomb. 2021;37(1):40–46.